Compare Merck & Co., Inc. (MRK) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Wells Fargo & Co — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Wells Fargo & Co trades at $87.9 (market cap $261.45B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | WFC | |
|---|---|---|
Market Cap | $307.25B | $261.45B |
Sector | Health | Financials |
52-Week High | $129.52 | $96.40 |
52-Week Low | $77.60 | $73.42 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Wells Fargo (WFC) trades at $87.75, up 0.26% today, with a neutral technical signal and bullish moving averages. The stock shows improving fundamentals with 2025 revenue of $83.70B and net income of $21.34B, yielding a 25.97% net margin. Recent Q2 2026 earnings beat expectations with EPS of $1.96 versus $1.73 expected. Analyst consensus is mixed with a $97.36 price target, suggesting 11% upside. The bank continues growth initiatives post-asset cap removal, though net cash flow remains negative.
Outlook remains cautiously optimistic given valuation support (P/E 12.55) and dividend yield, but risks include net interest margin pressure and volatile cash flows. Institutional activity is mixed with some trimming positions. Earnings sustainability and loan growth execution are key catalysts for further upside, while macroeconomic sensitivity poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
